Skip to main content
PRLD logo

PRLD · Prelude Therapeutics Inc

Track PRLD — free
$3.23 -0.03 (-0.77%) At close · Nov 20
Market Cap
$258.63M
Shares
80.07M
Volume · Nov 20 300.1K Avg daily vol (3M) 434.45K

Price & Indicators

 

Key stats

Close
$3.23
Fri 20 Nov
Open
$3.21
Fri 20 Nov
Average volume, 30 days
360K
shares a session
Short interest
4.2M
5.2% of shares · 9.1 days to cover
Day range
$3.17$3.30
Open $3.21 Close $3.23
52-week closing range
$1.35$6.63
Close $3.23 51.3% under the high
Short volume, last session
60%
Last earnings
Nov 16, 2026
Latest filing
10-Q · Nov 16
Price history
Sep 2020 to Nov 2026

Up next

Mar 9, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 16
Quarterly report 10-Q FY2026 Q3, ended Sep 30
PRT13722 Phase 1 underway with Eli Lilly combination support

Prelude began Phase 1 enrollment for PRT13722 after September 2026 FDA clearance and entered an October 2026 clinical trial collaboration with Eli Lilly and Company to evaluate abemaciclib and imlunestrant combinations in HR+/HER2- breast cancer.

Revenue $5.65M ▼ 13.1% Net loss $12.54M Diluted EPS -$0.12
Read from the MD&A section
3 source passages
Prelude is a precision oncology company built on a foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients. In September 2026, the FDA cleared us to proceed with a Phase 1 study under our IND Application for PRT13722. Enrollment of the phase 1 study of PRT13722 in HR+ breast cancer is underway (NCT07905001). In October 2026, we entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company (“Lilly”) for supply of its CDK4/6 kinase inhibitor, abemaciclib, and its oral estrogen receptor antagonist, imlunestrant. The agreement supports the evaluation of our clinical development candidate PRT13722 in combinations with abemaciclib and imlunestrant in the existing Phase 1 trial in patients with HR+/HER2- breast cancer. Open the document at this passage
Nov 16
Current report 8-K
PRT13722 enrollment underway with cash runway into 2028

Prelude Therapeutics began Phase 1 enrollment for PRT13722 in HR+/HER2- breast cancer, expects proof-of-concept data in the 2nd half of 2027, and expects cash to fund operations into the second quarter of 2028.

Financial results, Regulation FD disclosure
3 source passages
Enrollment of Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer is underway; initial proof of concept data anticipated in the 2nd half of 2027 The Company initiated enrollment into the Phase 1 study of PRT13722 in HR+ breast cancer in Q4 2026. The Company anticipates disclosure of initial proof of concept data from this study in the 2nd half of 2027. Cash, cash equivalents, restricted cash and marketable securities as of September 30, 2026 were $142.7 million. The Company anticipates that its existing cash, cash equivalents, restricted cash and marketable securities will fund Prelude’s operations into the second quarter of 2028. Open the document at this passage
Oct 20
Investor event
Insight Option Decision Pending; CAT6 Degrader Data Due 2027

The first half is expected to bring clarity on whether Insight exercises its option, worth $100 million in non-dilutive financing. Initial proof-of-concept data for the CAT6 degrader program is anticipated in the second half of 2027.

3 source passages
we're going to have clarity if you will on whether or not insight will exercise the option right if the option were to be exercised is $100 million in non-dilutive financing by the second half, or in the second half of 2027, we anticipate revealing initial proof of concept data for our CAT6 degrader program Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$21.57M
Trailing 12 months
Net income (TTM)
−$53.31M
Trailing 12 months
Revenue growth YoY
-13.1%
Year over year
Operating margin
-283.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-10.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$140.00M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+35.4%
Year over year · more shares
Price change (1Y)
+101.9%
Trailing year
Short interest
5.2%
Latest settlement · 9.1 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −22%
below
Price vs 50-day avg −16%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 36%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −11%
trailing
6-month return −8%
trailing
YTD return +11%
this year
Relative strength +1%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+22% holders QoQ · +23 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.22% of shares out · ▼ -18.0% MoM · 9.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
94 holders — near 3-yr high, broad support
Squeeze score 51
elevated · 0–100
Fundamentals
Strong
Revenue growth +73%
Y/Y
EPS growth +23%
Y/Y
Free cash flow $-56.4M
Balance sheet $35.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 109%
annualized · 1-yr
Max drawdown −51%
past year
ATR 8.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−22% Bearish
Price vs 50-day avg
−16% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
36% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+22% holders QoQ · +23 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.22% of shares out · ▼ -18.0% MoM · 9.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
94 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $3 · 36% Range high $7
vs 200-day avg -22% vs 50-day avg -16%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
complete and durable responses 100% November 2026 —
Complete Response Rate as Monotherapy 100% November 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PRLD
Prelude Therapeutics Inc
this stock
$258.63M +11.4% +73.4% — 5.2%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
94
% held
65.1%
Net QoQ
+2.5M sh
Top holder
ORBIMED ADVISORS LLC
Held Float
View
Held by Funds
Fund positions
82
View
Short & Settlement
Short Interest Falling
Shares short
4.2M
Days to cover
9.1d
Change
-919.9K sh
View
Short Volume
Short vol %
60%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
4.8K
Value
$18.5K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
39.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$12.1M
Net income (FY)
$-99.5M
EPS diluted
$-1.29
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 16, 2026
This year
23

Prelude began Phase 1 enrollment for PRT13722 after September 2026 FDA clearance and entered an October 2026 clinical trial collaboration with Eli Lilly and Company to evaluate abemaciclib and imlunestrant combinations in HR+/HER2- breast cancer.

View
Exempt Offerings
Offering
$50.0M
Filed
Aug 28, 2020
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 2, 2026
Last webcast
Nov 16, 2026
View
Investor Relations
Latest news
Prelude Therapeutics Reports Thir…
Published
Nov 16, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
PRLD -6.4% -11.0% -7.7% -16.8% +11.4%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +2.2% -1.8% +1.5% -8.0% +10.2%
Key facts CIK 1678660 CUSIP 74065P101 13F (30d) 104 filings 90 filers Visit website Investor relations